GSK says RSV vac­cine trig­gered im­mune re­sponse in adults as young as 50 years old

GSK read out Phase III re­sults on Wednes­day sug­gest­ing that its res­pi­ra­to­ry syn­cy­tial virus vac­cine — cur­rent­ly ap­proved for the 60-and-old­er pop­u­la­tion — may trig­ger an im­mune re­sponse in slight­ly younger adults.

Arexvy’s im­mune re­sponse in adults ages 50 to 59 ap­peared non-in­fe­ri­or to that in adults 60 and old­er, in­clud­ing in a sub­group with un­der­ly­ing med­ical con­di­tions, ac­cord­ing to GSK. While RSV typ­i­cal­ly pos­es the great­est threat to in­fants and old­er adults, co­mor­bidi­ties such as COPD or asth­ma can put oth­ers at a height­ened risk.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER